Tenax Therapeutics, Inc. TENX shares are trading higher by over 10% in the premarket session on Wednesday. The stock gained 31% in yesterday’s regular trading session.
The company said yesterday that U.S. regulators for patents and trademarks allowed its patent application related to its heart failure therapy, levosimendan.
The patent application claims covering the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955).
Levosimendan is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.
The patent also covers various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients.
This new patent, once granted, will provide significant added IP protection through December 2040.
Tenax Therapeutics said it has North American rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan.
“This provides additional rationale for the future development of various drug-drug combinations with levosimendan,” said Chris Giordano, President & Chief Executive Officer of Tenax Therapeutics.
Read Next: Carvana Plans Turnaround With Strategic Restructuring, Stock Rebound And Debt Overhaul: Report
Price Action: TENX shares are trading higher by 10% to $12.60 premarket on the last check Wednesday.
Photo via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
